Het landelijk platform CUPP-NL is officieel in de lucht! #primairetumoronbekend#CUP https://t.co/TFVZ16vV4a Laten we de handen ineen slaan! https://t.co/sGj451RaLO
Today, three of the authors have retracted "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" Read the Retraction notice and statement from The Lancet https://t.co/pPNCJ3nO8n
RCT with oral ADT. Positive primary end point; sustained testosterone suppression to castrate levels through 48w. Less cardiovascular events (HR 0.46; 95% CI, 0.24 to 0.88). Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Shore et al
Geriatrician-led CGA + intervention integraded with usual oncological care leads to better quality of life, less unplanned hospital admissions and less treatment discontinuation in older patient receiving #chemotherapy. Nice work from @KhengSoo1#VirtualASCO#ASCO20#GeriONC
Impact of Progression at Baseline and On-Treatment Progression Events in Three Large Prostate Cancer Trials - Beyond the Abstract https://t.co/e8GqFPjRMG
Een thread over de nieuwe mogelijkheid om uitgebreide #DNA diagnostiek te ondergaan bij @ErasmusOncology.
Wij geloven dat #zorgopmaat de toekomst heeft voor patiënten met #kanker
We’re not there yet #patientselection#timing#method. Trédan O, Wang D, Pissaloux P, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol2019; 30(5):757-765.
Blijft ‘n fascinerend fenomeen: Sonja Bakker en waarom mensen er steeds weer intuinen. Stevig commentaar in @volkskrant vandaag. Ons boek #VETbelangrijk (co-auteur @BoonMariette) wordt ook besproken, dat volgens de VK ‘wél hout snijdt’ en nog steeds in bestsellerlijsten staat.
The >2 year follow-up results of the randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer in @Annals_Oncology show the clinical benefit is durable. https://t.co/lRLQLBY1HG
Important reminder: lymph node progression under #immunotherapy may not be tumor progression. Specially relevant in the neoadjuvant setting. Why #pathology matters. #ASCO19#LCSM
CITN12 1st prospective study of #pembrolizumab in people living with #HIV & #cancer demonstrates safety and activity in several HIV-malignancies https://t.co/vEeiuW04e6 #ASCO19
Androgen deprivation therapy has been considered to be the primary standard of care for those with low volume metastatic prostate cancer.
However, there's now another option. https://t.co/w01cDXkrvO